These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis. Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014 [No Abstract] [Full Text] [Related]
16. The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor. Kaiser TM; Kell SA; Kusumoto H; Shaulsky G; Bhattacharya S; Epplin MP; Strong KL; Miller EJ; Cox BD; Menaldino DS; Liotta DC; Traynelis SF; Burger PB Mol Pharmacol; 2018 Feb; 93(2):141-156. PubMed ID: 29242355 [No Abstract] [Full Text] [Related]
17. Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. Gielen M; Le Goff A; Stroebel D; Johnson JW; Neyton J; Paoletti P Neuron; 2008 Jan; 57(1):80-93. PubMed ID: 18184566 [TBL] [Abstract][Full Text] [Related]
18. The N-terminal domains of both NR1 and NR2 subunits determine allosteric Zn2+ inhibition and glycine affinity of N-methyl-D-aspartate receptors. Madry C; Mesic I; Betz H; Laube B Mol Pharmacol; 2007 Dec; 72(6):1535-44. PubMed ID: 17878266 [TBL] [Abstract][Full Text] [Related]
19. A novel NMDA receptor positive allosteric modulator that acts via the transmembrane domain. Wang TM; Brown BM; Deng L; Sellers BD; Lupardus PJ; Wallweber HJA; Gustafson A; Wong E; Volgraf M; Schwarz JB; Hackos DH; Hanson JE Neuropharmacology; 2017 Jul; 121():204-218. PubMed ID: 28457974 [TBL] [Abstract][Full Text] [Related]
20. New advances in NMDA receptor pharmacology. Ogden KK; Traynelis SF Trends Pharmacol Sci; 2011 Dec; 32(12):726-33. PubMed ID: 21996280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]